-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 18th, BioVaxys Technology Corp.
BioVaxys submitted CoviDTH's pre-IND meeting application and briefing package to the FDA's Center for Biologics Evaluation and Research (CBER) in March this year
FDA may choose not to grant pre-IND review due to substantive reasons, for example, it is too early in the product development stage, or it does not provide sufficient basis for review
Note: The original text has been deleted